Rampart1 Posted - 10 minutes ago

$JAGX last time in 2021 jagx announced their abstract for ASCO April 29. We may see same thing, but not sure if P3 data will delay it etc. But Lisa said they going so ok. 💪🏻 https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-and-napo-pharmaceuticals-announce-title-abstract

Rampart1 Posted - 34 minutes ago

$JAGX news this week for sure. IMHO. ASCO announcement would be duh bombsville.

TheSkyLark7 Posted - 1 hour ago

$JAGX what ya average in here

diamondhandzape Posted - 1 hour ago

$JAGX 🚨🚨🚨🚨🚨 What are the chances that we get halted next week one day and open at $1.50+ and squeeze like $5-$10 🚀🚀🚀🚀🚀🚀

Pipcrusher001 Posted - 1 hour ago

$JAGX have a blessed weekend, yall. Next week, we rise from the ashes. (Let's get some P3 news!)

rubiconjay Posted - 2 hours ago

$JAGX $SPCB $VXRT $RVYL $KTRA A Little Weekend Reminder That The System Is The Enemy! It's NOT THE COMPANY! https://youtu.be/pdyx0jl7Las?si=uMZdT4D2-gXLVDQ6

EdPowell4Trump Posted - 2 hours ago

$JAGX

ZiggyPG Posted - 3 hours ago

$JAGX Some crazy volume the past week. Financials look horrible though! What's the event here or is just another P&D?

g553194 Posted - 3 hours ago

$JAGX another good one for Monday is QTI. TWG JAGX QTI

jacksparo Posted - 4 hours ago

$JAGX I am expecting a potential good trade next week or so here team! As soon as I get the plan ready will email you! You all saw my last plan Wednesday night how it did work great ✅📈✅!

1WELLDONE Posted - 4 hours ago

$JAGX Nice accumulation day. Loaded ready for next week. Long and strong.

magic2007 Posted - 4 hours ago

$JAGX Remember

grijalja Posted - 4 hours ago

$JAGX Quietly accumulating during the AH… have a good weekend Bulls

warrants_Moon Posted - 4 hours ago

$JAGX with the R/S off the table, what is it bears? Buyout after fast track designation from p3 top line results?

Joe1414 Posted - 4 hours ago

$JAGX p3 data soon

rubiconjay Posted - 4 hours ago

$JAGX

BellR Posted - 4 hours ago

$JAGX P3 Data releasing …ugh!

WolfOFMercerSt Posted - 4 hours ago

$JAGX LADIES & GENTLEMAN 14Cents is the Bottom here & there is major Support with plenty of upside. BUY YOUR SHARES NOW & DONT CHASE LIKE LAST MONDAY WHEN IT RAN 100%…

Heeeeheee Posted - 4 hours ago

$JAGX Take that take that. Heeeeeheeee

ThaDinkels Posted - 4 hours ago

$JAGX the same people shorting are the same people pumping. They write bear posts and short to drop it down the buy shares cheap run it up with copy past bull posts then rinse results. 17 again Monday w no news. They are just flipping and day trading until the news. They better be careful and not get caught short though

EdPowell4Trump Posted - 4 hours ago

$JAGX seen this precursor behavior prior to big moves before … don’t be surprised if P3 is released with the next 7 days ….

EdPowell4Trump Posted - 4 hours ago

$JAGX $10+

Rampart1 Posted - 4 hours ago

$JAGX looks someone knows something coming and stealing your shares. 🤔✅

eennels0157 Posted - 4 hours ago

$JAGX See the bigger picture folks! JAGX announced the appointment of a new senior leadership position to execute the company's in-licensing growth strategy in the area of cancer and GI supportive care...a $4 billion global market. Would not have created such a position if the company did not believe positive results from phase 3 study was not coming out sooner than we expect. Get ready for a bigger move in the stock price $$$

eennels0157 Posted - 4 hours ago

$JAGX “We are expanding our footprint beyond HIV-related supportive care to include cancer-related supportive care, and the in-license of Gelclair is a first building block while we await the forthcoming results from our pivotal Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea,” Conte added. Jaguar's expectation from the RELEASE OF IT'S PHASE 3 CLINICAL CANCER RESULTS ANY DAY NOW is that the placebo controlled OnTarget trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes. The OnTarget trial is evaluating the effectiveness of crofelemer's novel mechanism of action - the modulation of two gastrointestinal chloride ion channels - to mitigate or substantially reduce chronic cancer therapy-related diarrhea. The GLOBAL MARKET for such treatment is expected to be $4 BILLION and THERE IS NO COMPETITION!!

eennels0157 Posted - 4 hours ago

$JAGX Catherine Miller Collis previously served as the Chief Commercial Officer at Vibrant Gastro, a company dedicated to developing and commercializing innovative therapies for gastrointestinal disorders and diseases. She has a track record of envisioning and overseeing innovative commercial strategies to deliver sales targets, secure access, and manage P&L goals. Collis has launched multiple blockbuster brands in the US, EU, China, and Japan, in specialty and rare disease areas such as CNS/neurology, GI, women’s health, cancer pain, neuropathic pain, and hospital/acute pain.

Pktinfo Posted - 4 hours ago

$JAGX game over

eennels0157 Posted - 4 hours ago

$JAGX “Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and we are thrilled she has joined Jaguar’s team in the important role of Senior Vice President of Growth Strategy,” said Lisa Conte, Jaguar's president and CEO. “We are confident that her extensive commercial and business development experience will prove invaluable as we continue to evolve and execute our in-licensing growth strategy in the areas of cancer and GI supportive care, initiate the commercial launch of Gelclair, and focus on our ongoing mission to serve patients in need around the globe.”

EdPowell4Trump Posted - 4 hours ago

$JAGX 👊😎🔥

eennels0157 Posted - 4 hours ago

$JAGX NEW ANNOUNCEMENTS!! Jaguar Health, Inc. (JAGX) on April 17th, announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy. Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect "We are expanding our footprint beyond HIV-related supportive care to include cancer-related supportive care, and the in-license of Gelclair is a first building block while we await the forthcoming results from our pivotal Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency." https://finance.yahoo.com/news/jaguar-health-appoints-biopharmaceutical-industry-123000571.html